JP2004505649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004505649A5 JP2004505649A5 JP2002519613A JP2002519613A JP2004505649A5 JP 2004505649 A5 JP2004505649 A5 JP 2004505649A5 JP 2002519613 A JP2002519613 A JP 2002519613A JP 2002519613 A JP2002519613 A JP 2002519613A JP 2004505649 A5 JP2004505649 A5 JP 2004505649A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- nucleic acid
- substance
- acid sequence
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 35
- 150000007523 nucleic acids Chemical group 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 101000605518 Homo sapiens Kallikrein-15 Proteins 0.000 description 8
- 102100038301 Kallikrein-15 Human genes 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22485300P | 2000-08-11 | 2000-08-11 | |
| PCT/CA2001/001141 WO2002014485A2 (en) | 2000-08-11 | 2001-08-10 | Kallikrein gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004505649A JP2004505649A (ja) | 2004-02-26 |
| JP2004505649A5 true JP2004505649A5 (enExample) | 2008-10-02 |
Family
ID=22842508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002519613A Pending JP2004505649A (ja) | 2000-08-11 | 2001-08-10 | 新規なカリクレイン遺伝子 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7199229B2 (enExample) |
| EP (1) | EP1309703B1 (enExample) |
| JP (1) | JP2004505649A (enExample) |
| AT (1) | ATE330017T1 (enExample) |
| AU (2) | AU2001287384B2 (enExample) |
| CA (1) | CA2418422C (enExample) |
| DE (1) | DE60120712T2 (enExample) |
| ES (1) | ES2266245T3 (enExample) |
| WO (1) | WO2002014485A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022497B1 (en) * | 1999-03-11 | 2006-04-04 | Mt. Sinai Hospital | Human kallikrein-like genes |
| US9012141B2 (en) * | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| DE60120712T2 (de) | 2000-08-11 | 2007-07-19 | Mount Sinai Hospital, Toronto | Kallikrein gen |
| EP1330652B1 (en) * | 2000-10-27 | 2007-06-27 | Mount Sinai Hospital | Method for detecting ovarian cancer based on human kallikrein 6 (hk6) |
| US7741019B2 (en) | 2000-11-01 | 2010-06-22 | Mount Sinai Hospital | Detection of ovarian cancer |
| WO2002097438A1 (en) * | 2001-05-25 | 2002-12-05 | Mount Sinai Hospital | Method of detecting and monitoring prostate and ovarian cancers |
| WO2003033731A2 (en) * | 2001-10-16 | 2003-04-24 | Mount Sinai Hospital | Methods for detecting ovarian cancer |
| US20060159616A1 (en) * | 2002-08-28 | 2006-07-20 | Mount Sinai Hospital | Methods for detecting endocrine cancer |
| CA2497058A1 (en) * | 2002-08-28 | 2004-03-11 | Mount Sinai Hospital | Methods for detecting breast and ovarian cancer |
| WO2004029285A2 (en) * | 2002-09-26 | 2004-04-08 | Mount Sinai Hospital | Methods for detecting endocrine cancer |
| WO2004075713A2 (en) * | 2003-02-26 | 2004-09-10 | Mount Sinai Hospital | Multiple marker assay for detection of ovarian cancer |
| US20060141471A1 (en) * | 2003-02-27 | 2006-06-29 | Mount Sinai Hospital | Assay for detection of renal cell carcinoma |
| CA2468651A1 (en) * | 2003-06-13 | 2004-12-13 | Eleftherios P. Diamandis | Detection of neurodegenerative diseases |
| US20060269971A1 (en) * | 2003-09-26 | 2006-11-30 | Mount Sinai Hospital | Methods for detecting prostate cancer |
| EP1711616A1 (en) * | 2004-01-28 | 2006-10-18 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with kallikrein 15 (klk15) |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| ES2741730T3 (es) | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
| US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
| EP2825195A4 (en) | 2012-03-12 | 2015-10-07 | Advaxis Inc | INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022497B1 (en) | 1999-03-11 | 2006-04-04 | Mt. Sinai Hospital | Human kallikrein-like genes |
| JP2004501637A (ja) * | 2000-06-26 | 2004-01-22 | スージェン・インコーポレーテッド | 新規プロテアーゼ |
| JP2004515220A (ja) * | 2000-07-21 | 2004-05-27 | インサイト・ゲノミックス・インコーポレイテッド | プロテアーゼ |
| DE60120712T2 (de) * | 2000-08-11 | 2007-07-19 | Mount Sinai Hospital, Toronto | Kallikrein gen |
| US6962793B2 (en) * | 2000-10-27 | 2005-11-08 | Mount Sinai Hospital | Methods for detecting Alzheimers disease |
| EP1330652B1 (en) * | 2000-10-27 | 2007-06-27 | Mount Sinai Hospital | Method for detecting ovarian cancer based on human kallikrein 6 (hk6) |
| US7741019B2 (en) * | 2000-11-01 | 2010-06-22 | Mount Sinai Hospital | Detection of ovarian cancer |
| WO2002097438A1 (en) * | 2001-05-25 | 2002-12-05 | Mount Sinai Hospital | Method of detecting and monitoring prostate and ovarian cancers |
| WO2003033731A2 (en) * | 2001-10-16 | 2003-04-24 | Mount Sinai Hospital | Methods for detecting ovarian cancer |
| AU2003213960A1 (en) | 2002-04-04 | 2003-10-20 | Mount Sinai Hospital | Methods for detecting ovarian cancer |
| CA2497058A1 (en) | 2002-08-28 | 2004-03-11 | Mount Sinai Hospital | Methods for detecting breast and ovarian cancer |
| US20060159616A1 (en) | 2002-08-28 | 2006-07-20 | Mount Sinai Hospital | Methods for detecting endocrine cancer |
| WO2004029285A2 (en) | 2002-09-26 | 2004-04-08 | Mount Sinai Hospital | Methods for detecting endocrine cancer |
| WO2004075713A2 (en) | 2003-02-26 | 2004-09-10 | Mount Sinai Hospital | Multiple marker assay for detection of ovarian cancer |
| US20060141471A1 (en) | 2003-02-27 | 2006-06-29 | Mount Sinai Hospital | Assay for detection of renal cell carcinoma |
| CA2468651A1 (en) | 2003-06-13 | 2004-12-13 | Eleftherios P. Diamandis | Detection of neurodegenerative diseases |
| US20060269971A1 (en) | 2003-09-26 | 2006-11-30 | Mount Sinai Hospital | Methods for detecting prostate cancer |
-
2001
- 2001-08-10 DE DE60120712T patent/DE60120712T2/de not_active Expired - Lifetime
- 2001-08-10 AU AU2001287384A patent/AU2001287384B2/en not_active Ceased
- 2001-08-10 AT AT01966837T patent/ATE330017T1/de not_active IP Right Cessation
- 2001-08-10 AU AU8738401A patent/AU8738401A/xx active Pending
- 2001-08-10 EP EP01966837A patent/EP1309703B1/en not_active Expired - Lifetime
- 2001-08-10 JP JP2002519613A patent/JP2004505649A/ja active Pending
- 2001-08-10 US US10/344,394 patent/US7199229B2/en not_active Expired - Fee Related
- 2001-08-10 ES ES01966837T patent/ES2266245T3/es not_active Expired - Lifetime
- 2001-08-10 WO PCT/CA2001/001141 patent/WO2002014485A2/en not_active Ceased
- 2001-08-10 CA CA2418422A patent/CA2418422C/en not_active Expired - Fee Related
-
2007
- 2007-03-29 US US11/729,560 patent/US7507403B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004505649A5 (enExample) | ||
| CA2418422A1 (en) | Novel kallikrein gene | |
| FI121014B (fi) | Sinkkisormiproteiinijohdannaisia ja niiden menetelmiä | |
| US7700755B2 (en) | Helicobacter pylori CAI antigen | |
| EP0643770B1 (en) | Helicobacter pylori cytotoxin associated immunodominant antigen useful for vaccines and diagnostics | |
| JP2005517422A (ja) | 代替抗体ならびにその調製方法および使用 | |
| CA2247285A1 (en) | Human tumor necrosis factor delta and epsilon | |
| US20070154933A1 (en) | Reagents and Methods for Identifying Gene Targets for Treating Cancer | |
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| CA2477195C (en) | Deleted sequence in m. tuberculosis, method for detecting mycobacteria using these sequences and vaccines | |
| JP2006506042A (ja) | Ｌａ１−ラクトバシルス株のゲノム | |
| WO2008074079A1 (en) | Identification of candidate vaccine antigens from dichelobacter nodosus | |
| JP2001501809A (ja) | カンディダ アルビカンスからの新規ｔｆｉｉｂ転写ファクター、それをコード化する核酸配列、及びカンディダ アルビカンス増殖の阻害のためのスクリーニング方法 | |
| JP2004515215A5 (enExample) | ||
| JP2001522605A5 (enExample) | ||
| JPWO1995010612A1 (ja) | ポルフィロモナス・ジンジバリスのフィンブリリンタンパク | |
| CN110066882B (zh) | 检测肠球菌属细菌中五种糖肽类药物耐药基因的特异性引物和探针组合及应用 | |
| JP2004533848A5 (enExample) | ||
| CA2418848A1 (en) | Cng2b: a novel human cyclic nucleotide-gated ion channel | |
| US20070243204A1 (en) | Helicobacter pylori proteins useful for vaccines and diagnostics | |
| GB2636832A (en) | Uses, methods, polypeptides and polynucleotides | |
| JP7199691B2 (ja) | カテプシンｅに強く結合し活性化するペプチド | |
| KR101808916B1 (ko) | 보툴리눔 신경독소 ｃ형 단백질에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 | |
| CA2385266A1 (en) | Novel cell cycle checkpoint genes and proteins encoded thereby | |
| WO2015046737A1 (ko) | 리스테리아의 병원성 조절인자 prfa 단백질과 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 |